Abstract
Purpose
To describe a survey of the use of ocriplasmin by members of the British and Eire Association of VitreoRetinal Surgeons (BEAVRS) for VitreoMacular Traction (VMT) and Full Thickness Macular Hole (FTMH) and compare it to published MIVI TRUST trial data.
Methods
All 173 BEAVRS members were contacted by email in October 2014 requesting data on all cases treated with ocriplasmin up to that date. The total number of cases, FTMH closure rate, VMT release rate and the frequency of adverse events were recorded. Results were compared with trial data.
Results
48 members responded reporting results from 241 eyes. The respective BEAVRS and MIVI TRUST trial closure rates for small FTMHs were 42.1 and 58.3% (P=0.09) and for medium FTMH 12.7 and 36.7% (P=0.01). The respective VMT release rates were 34.1 and 37.4% (P=NS). Retinal detachment was observed in 3.3% of the BEAVRS cohort compared with 0.4% in MIVI TRUST. Reduction in visual acuity to <6/60 was observed in 5.8% of the BEAVRS cohort and 0.6% in MIVI TRUST. Other complications not reported in the MIVI TRUST trial included an increase in FTMH basal diameter following unsuccessful ocriplasmin use in 46.9% of BEAVRS cases and zonular instability at the time of subsequent phacoemulsification in 2.4%.
Conclusion
Macular hole closure rates were lower in the BEAVRS survey than published in the MIVI TRUST trial data. The incidence of adverse events was greater than previously reported. The reasons for these disparities are unknown but could include positive reporting bias inherent to retrospective surveys, treatment and population differences.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola S et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 2012; 367 (7): 606–615.
Kaiser PK, Kampik A, Kuppermann BD, Girach A, Rizzo S, Sergott RC . Safety profile of ocriplasmin for the pharmacologic treatment of symptomatic vitreomacular adhesion/traction. Retina 35 (6): 1111–1127.
Haller JA, Stalmans P, Benz MS, Gandorfer A, Pakola SJ, Girach A et alMIVI-TRUST Study Group. Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials. Ophthalmology 2015; 122 (1): 117–122.
Tibbetts MD, Reichel E, Witkin AJ . Vision loss after intravitreal ocriplasmin: correlation of spectral –domain optical coherance tomography and electroretinography. JAMA Ophthalmol 2014; 132 (4): 487–490.
Fahim AT, Khan NW, Johnson MW . Acute panretinal structural and functional abnormalities after intravitreous ocriplasmin injection. JAMA Ophthalmol 2014; 132 (4): 484–486.
Keller J, Haynes RJ . Zonular dehiscence at the time of combined vitrectomy and cataract surgery after intravitreal ocriplasmin injection. JAMA Ophthalmol 2015; 133 (9): 1091–1092.
Hager A, Seibel I, Riechardt A, Rehak M, Joussen AM . Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes? Br J Ophthalmol 2015; 99 (5): 635–638.
Qiu TG . Ocriplasmin and Muller Glia. Adv Ophthalmol Vis Syst 2014; 1 (1): 2.
Jackson TL, Antcliff RJ, Hillenkamp J, Marshall J . Human retinal molecular weight exclusion limit and estimate of species variation. Invest Ophthalmol Vis Sci 2003; 44 (5): 2141–2146.
Colyear BH, Pischel DK . Clinical tears in the retina without detachment. Am J Ophthalmol 1956; 41: 773–792.
Linder B . Acute posterior vitreous detachment and its retinal complications. Acta Ophthalmol 1966; 87: 1–108.
Davis MD . Natural history of retinal breaks without detachment. Arch Ophthalmol 1974; 92: 183–194.
Wakely L, Rahman R, Stephenson J . A comparison of several methods of macular hole measurement using optical coherence tomography, and their value in predicting anatomical and visual outcomes. Br J Ophthalmol 2012; 96 (7): 1003–1007.
Dugel P, Regillo C, Eliott D . Characterization of anatomic and visual function outcomes in patients with full-thickness macular hole in ocriplasmin phase 3 trials. Am J Ophthalmol 2015; 160 (1): 94–99.
Greven MA, Garg S, Chiu B, Shah SP, Wolfe J, Fine HF et al. Vitrectomy After Ocriplasmin for VitreOmacular Adhesion Or Macular Hole (VAVOOM) Study. Br J Ophthalmol 2016; 100 (9): 1211–1215.
Warrow DJ, Lai MM, Patel A, Raevis J, Berinstein DM . Treatment outcomes and spectral-domain optical coherence tomography findings of eyes with symptomatic vitreomacular adhesion treated with intravitreal ocriplasmin. Am J Ophthalmol 2015; 159 (1): 20–30.
Steel DH, Sandinha MT, White K . The plane of vitreoretinal separation and results of vitrectomy surgery in patients given ocriplasmin for idiopathic macular hole. Invest Ophthalmol Vis Sci 2015; 56 (6): 4038–4044.
Tadayoni R Foveal Detachment after Idiopathic Macular Hole Surgery. Presented at Gonin society meeting 2014.
Delgado-RodrĂguez M, Llorca J . Bias. J Epidemiol Community Health 2004; 58 (8): 635–641.
Colognato H, Yurchenco P . Form and function: the laminin family of heterotrimers. Dev Dyn 2000; 218 (2): 213–234.
Acknowledgements
To members of the British and Eire Association of Vitreoretinal Surgeons who contributed their ocriplasmin data including: J Bainbridge, M Bindra, A Callear, A Caswell, S Charles, A Fitt, I Fawcett, T Fallon, C Goldsmith, R Haynes, R Hillier, M La Cour, A Laidlaw, S Lesnik-Oberstein, S Lett, L Membrey, M Muqit, R Newsom, J Park, N Patton, N Price, R Rahman, J Sharkey, J Smith, D Steel, V Tanner, D Vayalambrone, S Murjaneh, K Xue, R Zakir & H Zambarackji.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
RJ Haynes: Alcon ocriplasmin advisory board member. D Steel: Alcon Consultancy, Research funding. DAH Laidlaw: Alcon ocriplasmin advisory board member. This work received no support in the form of grants, equipment or drugs.
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Haynes, R., Yorston, D., Laidlaw, D. et al. Real world outcomes of ocriplasmin use by members of the British and Eire Association of Vitreoretinal Surgeons. Eye 31, 107–112 (2017). https://doi.org/10.1038/eye.2016.195
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2016.195
This article is cited by
-
Vitreomacular traction – a review
Eye (2025)
-
Intravitreal injection associated rhegmatogenous retinal detachment: outcomes of a European analysis
Graefe's Archive for Clinical and Experimental Ophthalmology (2021)
-
Mikrostrukturelle retinale Veränderungen nach pharmakologischer Vitreolyse mit Ocriplasmin – eine SD-OCT-gestützte Analyse
Der Ophthalmologe (2020)
-
It’s a gas! Pneumatic release of VMT
Eye (2017)
